KRN23

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Tumor-Induced Osteomalacia (TIO)

Conditions

Tumor-Induced Osteomalacia (TIO)

Trial Timeline

Sep 7, 2022 → Dec 22, 2023

NCT ID

NCT05357573

About KRN23

KRN23 is a approved stage product being developed by Kyowa Kirin for Tumor-Induced Osteomalacia (TIO). The current trial status is completed. This product is registered under clinical trial identifier NCT05357573. Target conditions include Tumor-Induced Osteomalacia (TIO).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05357573	Approved	Completed	Sep 7, 2022	Dec 22, 2023	Tumor-Induced Osteomalacia (TIO)
NCT04842032	Approved	Completed	Nov 1, 2021	Dec 18, 2023	X-linked Hypophosphatemia (XLH)
NCT04842019	Approved	Completed	Sep 28, 2021	Aug 17, 2023	X-linked Hypophosphatemia (XLH)
NCT04308096	Phase 3	Completed	Jan 9, 2018	Dec 4, 2020	XLH
NCT03233126	Phase 3	Completed	Jul 6, 2017	Feb 17, 2020	X-linked Hypophosphatemic Rickets/Osteomalacia
NCT02722798	Phase 2	Completed	Apr 1, 2016	Oct 1, 2020	Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
NCT02312687	Phase 2	Completed	Jan 30, 2015	Nov 30, 2018	X-Linked Hypophosphatemia
NCT02181764	Phase 1	Completed	Jul 1, 2014	Jun 1, 2015	X-linked Hypophosphatemic Rickets/Osteomalacia
NCT01571596	Phase 1/2	Completed	Feb 1, 2012	Jun 1, 2014	X-linked Hypophosphatemia
NCT01340482	Phase 1/2	Completed	Apr 1, 2011	Oct 1, 2013	X-linked Hypophosphatemia

Competing Products

1 competing product in Tumor-Induced Osteomalacia (TIO)

See all competitors

Product	Company	Stage	Hype Score
KRN23	Kyowa Kirin	Phase 2	52

Other Products from Kyowa Kirin

Istradefylline PillApproved

MogamulizumabApproved

KRN23Approved

KHK4827-Active + KHK4827-PlaceboApproved

Cinacalcet HClApproved